These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31060855)

  • 1. Efficacy and Safety of BRAF Inhibitors With or Without MEK Inhibitors in BRAF-Mutant Advanced Non-Small-Cell Lung Cancer: Findings From a Real-Life Cohort.
    Dudnik E; Bar J; Peled N; Bshara E; Kuznetsov T; Cohen AY; Shochat T; Nechushtan H; Onn A; Agbarya A; Moskovitz M; Keren S; Popovits-Hadar N; Urban D; Mishaeli M; Rabinovich NM; Brenner R; Zer A; Rotem O; Roisman LC; Wollner M;
    Clin Lung Cancer; 2019 Jul; 20(4):278-286.e1. PubMed ID: 31060855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.
    Khunger A; Khunger M; Velcheti V
    Ther Adv Respir Dis; 2018; 12():1753466618767611. PubMed ID: 29595366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial.
    Planchard D; Besse B; Groen HJM; Souquet PJ; Quoix E; Baik CS; Barlesi F; Kim TM; Mazieres J; Novello S; Rigas JR; Upalawanna A; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2016 Jul; 17(7):984-993. PubMed ID: 27283860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint Inhibition in Addition to Dabrafenib/Trametinib for BRAF
    Hamidi S; Iyer PC; Dadu R; Gule-Monroe MK; Maniakas A; Zafereo ME; Wang JR; Busaidy NL; Cabanillas ME
    Thyroid; 2024 Mar; 34(3):336-346. PubMed ID: 38226606
    [No Abstract]   [Full Text] [Related]  

  • 5. A highly sensitive and specific real-time quantitative PCR for BRAF V600E/K mutation screening.
    Lung J; Hung MS; Lin YC; Jiang YY; Fang YH; Lu MS; Hsieh CC; Wang CS; Kuan FC; Lu CH; Chen PT; Lin CM; Chou YL; Lin CK; Yang TM; Chen FF; Lin PY; Hsieh MJ; Tsai YH
    Sci Rep; 2020 Oct; 10(1):16943. PubMed ID: 33037234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to dabrafenib plus trametinib on a rare BRAF mutation (V600_W604 deletion-insertion R) in an advanced non-small cell lung cancer patient.
    Tamura A; Inaba Higashiyama R; Yoshida T; Satozono Y; Ohe Y
    Thorac Cancer; 2024 Jun; 15(18):1454-1456. PubMed ID: 38766698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Dabrafenib Plus Trametinib in a Patient With an Uncommon Activating BRAF Mutation: A First in Non-Small Cell Lung Cancer.
    Sharp JA; Jones D; Rotow JK; Fidias PM; Bertino E; Owen DH
    J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38479107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRAF/MEK-targeted therapy in BRAF ex15 p.T599dup mutation-driven NSCLC: a case report.
    Jiang L; Yang P; Liu Y; Li J
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):162. PubMed ID: 38538919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-vessel vasculitis possibly induced by BRAF and MEK inhibitors for BRAF V600E positive lung adenocarcinoma.
    Ichikawa K; Ohno S; Kubo S; Nakajima H
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38719253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined BRAF, EGFR, and MEK Inhibition in Patients with
    Corcoran RB; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Middleton G; Muro K; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; Humblet Y; De Vos F; Jung AS; Brase JC; Jaeger S; Bettinger S; Mookerjee B; Rangwala F; Van Cutsem E
    Cancer Discov; 2018 Apr; 8(4):428-443. PubMed ID: 29431699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross-sectional and longitudinal analysis using two large national registries.
    Guha A; Jain P; Fradley MG; Lenihan D; Gutierrez JM; Jain C; de Lima M; Barnholtz-Sloan JS; Oliveira GH; Dowlati A; Al-Kindi S
    Cancer Med; 2021 Jun; 10(12):3862-3872. PubMed ID: 33982883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma.
    Hassel JC; Buder-Bakhaya K; Bender C; Zimmer L; Weide B; Loquai C; Ugurel S; Slynko A; Gutzmer R;
    Cancer Med; 2018 Jan; 7(1):95-104. PubMed ID: 29266761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dabrafénib and tramétinib in BRAF V600E mutated pediatric gliomas].
    Giorgis O; Doz F
    Bull Cancer; 2024 May; 111(5):429-430. PubMed ID: 38471994
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With
    Riely GJ; Smit EF; Ahn MJ; Felip E; Ramalingam SS; Tsao A; Johnson M; Gelsomino F; Esper R; Nadal E; Offin M; Provencio M; Clarke J; Hussain M; Otterson GA; Dagogo-Jack I; Goldman JW; Morgensztern D; Alcasid A; Usari T; Wissel P; Wilner K; Pathan N; Tonkovyd S; Johnson BE
    J Clin Oncol; 2023 Jul; 41(21):3700-3711. PubMed ID: 37270692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of
    Watanabe H; Inoue Y; Karayama M; Yazawa S; Mochizuka Y; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Enomoto N; Fujisawa T; Shinmura K; Inui N; Suda T
    JCO Precis Oncol; 2024 Apr; 8():e2300538. PubMed ID: 38662982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting
    Baik CS; Myall NJ; Wakelee HA
    Oncologist; 2017 Jul; 22(7):786-796. PubMed ID: 28487464
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SH003 Enhances the Anti-cancer Effects of Dabrafenib on Lung Cancer Harboring
    Choi YJ; Chung YH; Lee K; Jeong M; Ko SG
    Anticancer Res; 2024 May; 44(5):1905-1913. PubMed ID: 38677764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exceptionally long-lasting response to dabrafenib plus trametinib treatment in a patient with lung adenocarcinoma harboring the BRAF V600E mutation with high expression of PD-L1: A case report.
    Inoue T; Kunimasa K; Tamiya M; Kawamura T; Minami T; Nishino K
    Thorac Cancer; 2024 Apr; 15(11):929-933. PubMed ID: 38429896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Successful Use of BRAF/MEK Inhibitors in Aggressive BRAF-mutant Craniopharyngioma.
    Wu ZP; Wang YL; Wang LC; Liu ZY; Fan RR; Zan X; Liang RC; Yang JL; Zhou LX; Xu JG
    World Neurosurg; 2023 Dec; 180():e117-e126. PubMed ID: 37683921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetics-guided therapy in neuroendocrine carcinoma: response to BRAF- and MEK-inhibitors.
    Falkman L; Sundin A; Skogseid B; Botling J; Bernardo Y; Wallin G; Zhang L; Welin S; Lase I; Mollazadegan K; Crona J
    Ups J Med Sci; 2024; 129():. PubMed ID: 38716076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.